bullish in the next 12 months - I’m looking the bigger picture and am really interested in seeing this CEO skilfully repositioning DCN back to its glory’s.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%